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Background: Chronic hepatitis is a major public health problem. Hepatitis B virus is the primary cause, and
Hepatitis B and C together are responsible for 60% of cirrhosis and 80% of hepatocellular carcinomas. This study
measured the prevalence of HBsAg among Senegalese military to develop an appropriate strategy to prevent
cirrhosis and hepatocellular carcinoma.
Methods: We conducted a descriptive cross-sectional study among Senegalese military aged 25 to 60 years. A
sample of 1224 participants was selected following a two-level-stratification. The mark of surface HBs antigen
using chemiluminescence concerned 1195 participants. The presence of HBsAg was analyzed according to age,
marital status, alcohol consumption and glomerular filtration rate. Epi-info6fr and R software were used, respectively, for
data capture and analyses. A Chi-square test was performed to compare proportions considering a significance level of
5% and a confidence interval of 95%.
Results: The average age was 39.8 ± 9.2 years. Participants in the age groups of 25–34 years, 45–60 years and 35–44
years were respectively 30.7%, 34.4% and 34.9% of the sample. Married persons represented 82.6% of participants and
17.08% were single. Most participants were educated (99%), and 56% had reached at least secondary school level.
Alcohol consumption was at 11.5%. The HBsAg prevalence rate was 10.8% [9.1% to 12.7%] with a significant difference
between age groups (P < 0.001), which ranged from 5.6% for 45–60 years, 9.62% for 25–34 years to 16.9% for 35–44
years. Marital status and alcohol consumption did not affect the carriage of HBsAg. HBsAg prevalence was more
common among participants who had a glomerular filtration rate greater than 90 ml/min. Transaminases rate
exceeded the normal threshold for 43 participants (3.6%); the increase was 6.6% [2.7% to 11.8%] for HBsAg carriers and
3.2% [1.2% to 6.7%] for alcohol users.
Conclusions: The high prevalence of HBsAg in the military requires the implementation of an effective prevention and
care program to reduce the risk of cirrhosis and hepatocellular carcinoma and contribute to reducing the burden of
communicable diseases, such as hepatitis and HIV/AIDS, and non-communicable diseases.
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Chronic viral hepatitis is a worldwide major public
health problem, particularly in developing countries that
are facing a range of barriers to contain the epidemic
[1-5]. Approximately 9% of the world population is suf-
fering from chronic hepatitis. Lemoine et al. [1] reported
that 350–400 million of the 550 million people who* Correspondence: socef@who.int
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unless otherwise stated.were infected were infected by the hepatitis B virus
(HBV), 170–180 million by the hepatitis C virus (HCV)
and 15 million were due to the hepatitis D virus (HDV)
[1,6-8]. The poorest regions are the most affected [1,9].
HBV and HCV are responsible for 60% of cirrhosis and
80% of hepatocellular carcinomas, with more than one
million deaths annually, mainly in disadvantaged areas
[1,6,8,10]. These figures illustrate the role of hepatitis B,
which are also confirmed by other authors. The WHO
estimates that 2 billion people are infected with HBV
worldwide and approximately 380 million are chronicThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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million new infections occur annually, and 620,000
deaths due to HBV are reported worldwide [1,11]. The
prevalence of HBV is estimated between 8%-15% in en-
demic areas, such as Africa [1,12,13]. The prevalence in
the general population in Senegal was estimated as 11%
in 2012 according to the Ministry of Health. One study
of pregnant women at the Military Hospital of Ouakam,
between 2006 and 2009, showed a prevalence of HBV of
11.6% [14], which indicates the importance of the pres-
ence of the virus in the Senegalese general population.
This high prevalence justifies the implementation of a
national program against hepatitis and the integration of
the vaccine in the Expanded Immunization Program.
The fight against viral hepatitis B is not well structured
in the army. The current situation of infection preva-
lence is unknown. Therefore, one of the objectives of
this study was to determine the prevalence of HBsAg in
the military to develop strategies for cirrhosis and hepa-
tocellular carcinoma prevention.
Methods
We performed a descriptive and analytical cross-sectional
study in the Senegalese military in the period from May
2013 to February 2014.
Military aged men 25 to 60 years who were present in
the country during the survey were included in the study.
Soldiers who had less than 2 years of duty in the military
or were unable to answer the questions were excluded.
The enrolled population was divided into three (3) age
groups: 25–34, 35–44 and 45–60 years. The survey was
conducted in all Senegalese regions.
The sample size was calculated in the framework of
STEPS investigation in the military, which provided an
estimate of 1,296 men who were divided into three
strata. Each member was consistently linked to only one
training unit. Therefore, we proceeded with a first selec-
tion to determine the number of respondents in each
training unit using the human resources central data-
base. A second simple random sampling was performed
from the local unit file to identify participants for each
stratum.
Information regarding the socio-demographic (age,
gender, ethnicity, marital status, educational level, ranks…)
and behavioral characteristics (alcohol) of the subjects
were collected using a revised STEPS questionnaire [15].
For each participant, 5 ml of venous blood taken from
the elbow crease were collected in a dry test tube and
centrifuged. Sera were decanted and maintained at 4°C if
the analyses were not performed within 4 hours.
HBsAg was initially detected using the DETERMINE
HBs Agkit ® (Alere) and ARCHITECT HBsAg QUANTI-
TATIVE II (Abbott Diagnostics) ®. In a second step,
measurement of transaminases (AST and ALT) wasperformed using the controller from Biochemistry
Cobas400 ® of Roche Diagnostic laboratories and the
Spectrophotometer CYPRESS diagnostic ®.
Chronic renal disease was defined by a glomerular fil-
tration rate expressed in ml per min. The assessment of
the glomerular filtration rate (GFR) was performed using
the Modification of Diet in Renal Disease (MDRD) for-
mula [16]. Two stages were identified: Stage 1 repre-
sented a GFR value greater than 90 ml/min and Stage 2
a GFR between 60 and 90 ml / min [17,18].
Biochemical results were reported on the questionnaire.
Data were entered in Epi-info6 software and analyzed
using R software. The Chi-square test was performed to
compare proportions with 5% for the significance level
and 95% for the confidence interval (CI).
Participation was voluntary. Each participant signed a
consent letter at the beginning of the investigation and
had the opportunity to stop participating at any stage of
the process. All results were returned to the subjects,
and participants who were detected as HBs antigen car-
riers were referred to specialists for treatments.
Results
Instead of the 1,296 participants who were planned to be
involved in the survey, 1,224 soldiers were enrolled, and
1,195 were tested for HBsAg and transaminase levels.
The lack of HBsAg research for 29 participants was re-
lated to the mobility of soldiers and stock out of test,
while not their status.
The mean age was 39.8 years, and it was equal to the
median (normal distribution). The sample consisted
mostly of men with a sex ratio of 31.2, which followed
the personnel structure in the armed forces. Soldiers
were more represented (48.0%), followed by non-
commissioned officers (45.6%) and officers (6.4%).
Most participants were married (82.6%), singles rep-
resented 17.08% and other 0.32% of the sample. Ser-
ere (25.0%) and Ouolof (24.3%) ethnic groups were more
frequent, followed by Diola (18.3%) and Pulaar (16.3%).
Almost all respondents were literate (99.1%), and 56.0%
had at least achieved secondary level at school (See
Table 1).
The GFR identified two stages of chronic kidney dis-
ease (CKD) among participants: it was higher than
90 ml per min for 68% of participants (CKD stage 1) and
between 60 and 90 ml per min for 32% (CKD stage 2).
The prevalence of HBsAg was estimated at 10.8%
[9.1% to 12.7%], and it varied significantly between the
different age groups (P < 0.001). It was 9.62% [6.8% to
13.1%], 16.90% [13.4% to 20.8%] and 5.60% [3.6% to
8.3%] for the age groups 25–34, 35–44 and 45–60 years,
respectively (see Figure 1).
Table 2 shows that the carriage of HBsAg was not in-
fluenced by ethnic group, marital status and alcohol
Table 1 Demographic variables of respondents
Item Number Percentage CI95%
Age group
25-34years 376 30.71% [28.1%-33.4%]
35-44years 421 34.40% [31.7%-37.1%]
45-60years 427 34.89% [32.2%-37.6%]
Sex
Male 1186 96.90% [95.7%-97.8%]
Female 38 3.10% [2.2%-4.3%]
Professional category
Soldiers 588 48.04% [45.2%-50.8%]
Non-commissioned officers 558 45.59% [42.8%-48.5%]
Officers 78 6.37% [5.1%-7.9%]
Marital status
Married 1011 82.60% [80.4%-84.7%]
Single 209 17.08% [15.0%-19,3%]
Other 4 0.32%
Ethnic group
Serere 306 25.0% [22.6%-27.5%]
Ouolof 297 24.3% [21.9%-26.8%]
Diola 224 18.3% [16.2%-20.6%]
Pulaar 200 16.3% [14.3%-18.5%]
Mandingue 62 5.1% [3.9%-6.4%]
Other 135 11.0% [9.3%-12.9%]
Level of education
No education 12 0.9% [0.5%-1.7%]
Elementary Level 194 15.8% [13.8%-18.0%]
Average 313 25.6% [23.1%-28.1%]
High school 565 46.2% [43.3%-49.0%]
University 140 11.4% [9.7%-13.4%]
Figure 1 Prevalence rate of HBsAg carriers according to age
group among tested Senegalese soldiers.
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higher among participants who were classified as GFR
stage 1 (12.3%) compared to GFR stage 2 (7.7%) with a
p-value equal to 0.023. Similarly, the frequency was dif-
ferent according to rank and was greater for the soldiers
(13.6%) than non-commissioned officers (7.9%).
Transaminase rates were higher than the normal
threshold in 43 participants (3.6%); it was 6.6% [2.7% to
11.8%] among carriers of HBsAg and 3.2% [1.2% to
6.7%] among drinkers. However, an increase two times
greater than normal was exceptional.
Discussion
HBsAg prevalence is a public health problem, especially
in sub-Saharan Africa [5,19]. An area is classified as a
highly endemic area of hepatitis B [20,21] when HBsAg
seroprevalence is higher than 8% for adults. Kiire et al.
estimated the prevalence of hepatitis B in sub-Saharan
Africa between 9% and 12% [19], and the results of this
study confirmed that estimate. Indeed, the prevalence of
HBsAg was 10.8%, which shows the high endemicity of
hepatitis B among Senegalese troops. This result corre-
lated with the observed prevalence in the general popu-
lation (11%) in 2012 according to the Ministry of Health
[22,23], but it is lower than the prevalence among men
(21%) stated by Lo et al. in 2014 [23]. The difference in
the figures may be due to different target groups these
studies on HBsAg. Our study targeted subjects who were
apparently in good health, but the study conducted by
Gora was based on sick patients who were admitted to
the laboratory for further investigation. The current
practice in Senegal is the performance of exploratory
tests to confirm a clinical diagnosis. Therefore, there
may be an overestimation of the prevalence compared to
the general population. In fact, the observed prevalence
of HBsAg in pregnant women (11.57%), who are repre-
sentative of the general population, corroborates this hy-
pothesis [14].
A study in Nigeria estimated an HBV seroprevalence
14.6% with a higher frequency in the 20-30-year-old age
group [20]. Our study showed a slightly lower preva-
lence with a higher frequency among 35–44 year-olds.
Other authors had already reported a prevalence of HB
antigens that was higher among young adults aged 20 to
30 years [14,20]. The hypothesis stated for this finding
was that there were more frequent sexual activities
among young people. In our study, participants aged
35–44 years were more affected. The decreased preva-
lence rate in the elders might be related to the impact of
condom use campaigns and the extensive ongoing Na-
tional Hepatitis Program.
The military is considered a gateway group for sexually
transmitted diseases (STDs) and HIV/AIDS. The observed
prevalence of HBsAg in this study confirms the results of
Table 2 HBsAgseroprevalence according to certain socio-behavioral characteristics and chronic kidney disease in the
military
Item HBsAg positive*
Case Percentage (%) CI95% Pvalue
Ethnic group
Serere 38 12.6% [9.1%-16.9%] 0.68
Pulaar 22 11.3% [7.2%-16.7%]
Diola 23 10.5% [6.7%-15.3%]
Ouolof 24 8.4% [5.4%-12.2%]
Mandingue 6 9.8% [3.7%-20.2%]
Other 16 12.03% [7.0%-18.8%]
Professional category
Soldiers 78 13.6% [10.9%-16.7%] 0.0087
Non-commissioned officers 43 7.9% [5.8%-10.5%]
Officers 8 10.8% [4.8%-20.2%]
Marital status
Single 22 11.1% [7.1%-16.3%] 0.99
Married & other 107 10.7% [8.9%-12.8%]
Alcohol consumption
Yes 22 11.8% [7.6%-17.4%] 0.71
No 107 10.6% [8.8%-12.7%]
Chronic kidney disease: GFR
60-90 ml/min 30 7.7% [5.3%-10.8%] 0.023
>90 ml/min 99 12.3% [10.1%-14.8%]
*29 participants absent of HBsAg research.
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military, which had shown prevalence figures identical to
the general population [24].
HBsAg seroprevalence was 12.3% and 7.7% in partici-
pants with CKD stage 1 and stage 2, respectively. Diouf
et al. [25] reported an HBsAg seroprevalence (6.7%)
among patients receiving dialysis at Aristide Le Dantec
Hospital in Dakar (Senegal) that was comparable to our
patients with CKD stage 2.
Some authors attempted to link the carrying of HBsAg
and CKD [26-30]. In our study, 23.3% of patients with
HBsAg were CKD stage 2 versus 33.6% in patients who
were seronegative. These results need further investiga-
tion in a cohort or case–control study to elucidate the
causality.
Limitations
This study was conducted among soldiers who were se-
lected through incorporation screening based on com-
prehensive clinical data that satisfied medical fitness
criteria to serve in the armed forces. However, this med-
ical screening did not include liver function tests.Accordingly, symptomatic carriers should have been
eliminated. In addition, the sample was essentially com-
posed of men. The cross-sectional nature of the study
did not allow a demonstration of a causal relationshipConclusion
The highly endemic HBsAg prevalence mentioned in
this study is similar to the prevalence in the general
population. This finding makes sense because no specific
measures were taken to expect a different situation until
now. The detection of HBsAg is not yet introduced into
the army incorporation screening.
The interest of this work was to promote the introduc-
tion of Hepatitis B prevention in the overall fight against
non-communicable diseases in the army program and
communicable diseases, such as HIV/AIDS and hepa-
titis. Conducting awareness campaigns among the mili-
tary, periodic screening, improving access to treatment
and the training of health personnel will be the major
components of this program, which seeks to reduce cir-
rhosis and hepatocellular carcinoma morbidity and mor-
tality and the burden of non-communicable diseases.
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